CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Colegiales, Argentina

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

    This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated Follicular Lymphoma International Prognostic Index (FLIPI) 2-5 follicular lymphoma This study is composed of a screening period (up to 6 weeks before randomization, i.e., 42 days), a treatment period (30 months i.e., 125w), a safety follow-up period (90 days i.e., 3 months), and a survival follow-up period (up to 7 years after the last randomized patient). The enrollment will last approximately 34 months. The total duration of the study will be therefore approximately 10 years. Once a patient provides written consent, they may enter the screening phase, with a duration up to 6 weeks prior to randomization and initiation of treatment. Upon completion of the required assessments in the screening phase, and fulfillment of the eligibility criteria, patients will be randomized. Investigators will be requested to indicate their treatment choice among permitted immuno-chemotherapy regimens just before randomization. The treatment period for each patient starts with the first intake. The patients will receive protocol-specified treatments until: - inability to achieve a response at the end of induction phase (at M12 evaluation for experimental arm, and at M6 evaluation for control arms), - relapse or progression of the disease, - withdrawal of consent, - or unacceptable toxicity In the experimental arm, patients will be treated for 1 cycle of 3 weeks for mosunetuzumab and then 11 cycles of 4 weeks for mosunetuzumab and lenalidomide (47 weeks, around 11 months) during the induction phase, and for a maximum of 9 additional cycles of 8 weeks during the maintenance phase (72 weeks, around 17 months), up to around 125 weeks (30 months). Patients should start the maintenance phase 7 to 8 weeks after the start of last induction cycle (C12). In the control arm, patients will be treated for 8 or 6 cycles of 3 or 4 weeks for anti-CD20 mAb +cyclophosphamide-doxorubicine-vincristine-prednisone (CHOP) or anti-CD20 mAb + Bendamustine, respectively, depending on the assigned arm (24 weeks, around 5 months) during the induction phase, and for a maximum of 12 additional cycles of 8 weeks during the maintenance phase (96 weeks, around 22 months), up to around 125 weeks (30 months). Patients should start the maintenance phase, 6 to 7 or 7 to 8 weeks after the start of last induction cycle (C8 or C6). The option to cross-over from the control arm to the experimental arm is not allowed. All randomized patients will be followed for progression-free survival and overall survival using the same schedule. Patients will be followed up from End of treatment evaluation every 3 months during the first two years, then every 6 months during the next 3 years, then yearly until the end of study. The end of study will occur when all randomized patients have been followed-up for survival for at least 7 years (or discontinued study early).

    Phase

    3

    Span

    517 weeks

    Sponsor

    The Lymphoma Academic Research Organisation

    Verviers

    Recruiting

  • DESTINY Breast Respond HER2-low Europe

    This non-interventional study will investigate the effectiveness withT-DXd, the demographic and clinical characteristics of the patients, treatment patterns, tolerability, management of adverse drug reactions (ADRs), and patient experience of T-DXd in patients with HER2-low unresectable and/or metastatic breast cancer. Patients will be treated according to the proposed indication statement in the Summary of Product Characteristics (SmPC). No drug product will be administered as part of this study. Data on conventional chemotherapy (i.e., including but not limited to capecitabine, eribulin, gemcitabine, paclitaxel and nab-paclitaxel) will also be collected in a disease registry part of the study.

    Phase

    N/A

    Span

    254 weeks

    Sponsor

    Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

    Verviers

    Recruiting

  • Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

    Phase

    3

    Span

    333 weeks

    Sponsor

    European Organisation for Research and Treatment of Cancer - EORTC

    Verviers

    Recruiting

  • Study of Lacutamab in Peripheral T-cell Lymphoma

    Phase

    2

    Span

    330 weeks

    Sponsor

    The Lymphoma Academic Research Organisation

    Verviers

    Recruiting

  • Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry

    Phase

    N/A

    Span

    317 weeks

    Sponsor

    European Lung Cancer Working Party

    Verviers

    Recruiting

  • Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)

    Phase

    N/A

    Span

    330 weeks

    Sponsor

    Ipsen

    Verviers

    Recruiting

  • Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

    Phase

    N/A

    Span

    338 weeks

    Sponsor

    Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    Verviers

    Recruiting

  • Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

    This is a Phase 3, open-label, randomized clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Gedatolisib is an intravenously administered pan-PI3K/mTOR inhibitor. Palbociclib is a CDK4/6 inhibitor. Fulvestrant is a selective estrogen receptor degrader (SERD). Subjects will be assessed for PIK3CA status and then randomized to treatment arms according to their confirmed PIK3CA mutation status.

    Phase

    3

    Span

    212 weeks

    Sponsor

    Celcuity Inc

    Verviers

    Recruiting

  • A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

    Phase

    3

    Span

    496 weeks

    Sponsor

    Eli Lilly and Company

    Verviers

    Recruiting

1-9 of 9
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information